 |  | | ABOUT US | |
 | | PRODUCT | |
| | PIPELINE | |
| | INVESTOR RELATIONS | |
| | NEWS | |
| | CAREERS | |
| | | | | | | |||||||||||||||||||||||||||||||||||||||
 | |||||||||||||||||||||||||||||||||||||||||||||
|
| |
InterMune, Inc. is a biotechnology company focused on developing and commercializing innovative therapies in pulmonology and hepatology.
Our pulmonology pipeline includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY) and a New Drug Application (NDA) has been accepted for Priority Review by the FDA.
In hepatology, we are focused on expanding treatment options for patients suffering from hepatitis C virus (HCV) infections. The hepatology portfolio includes the HCV protease inhibitor compound RG7227 (ITMN-191) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program.
InterMune additionally sells Actimmune® (interferon gamma-1b), approved for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease. | |
| |
|||||||||||||||||||||||||||||||||||||||
| © InterMune 2004 | Terms and Conditions | Privacy Policy | |
| | | | |